MedPath

Hunan Fangsheng Pharmaceutical Co., Ltd.

Ownership
-
Established
1997-10-13
Employees
1.1K
Market Cap
-
Website
www.fangsheng.com.cn
Introduction

The company was founded in 2002. It is a health industry group integrating the pharmaceutical industry, the big health industry, and medical services, with innovative varieties of traditional Chinese medicine as the core, and has 6 major production bases across the country. Listed on the Shanghai Stock Exchange on December 5, 2014. From the establishment of the factory until now, the company has rapidly risen at a steady pace of development and has grown into one of the benchmark enterprises in the pharmaceutical industry in Hunan Province. It has been awarded major honors such as National Technological Innovation Demonstration Enterprise, Top 100 Chinese Pharmaceutical Brand Enterprise, China's Top 50 Pharmaceutical Industry Growth Enterprise, National Contract-abiding and Credit-worthy Enterprise, and the Hunan Governor's Quality Award Enterprise. At the same time, the “Fangsheng” trademark was recognized as a famous trademark in China in December 2013. The company is a high-tech enterprise engaged in R&D, production and sales of pharmaceuticals. The main categories are: cardiovascular medicine, orthopedic medicine, pediatric medicine, gynaecological medicine, respiratory medicine, anti-infective medicine, etc.; the main products are garcinia cambogia tablets, powerful loquat paste (honey), ezhemibu tablets, xuanqigen bone tablets, children's Jingxing cough tablets, Hesketong dispersible tablets, hemosideron tablets, vitamin B12 tablets, cefixime tablets, quintilene anti-inflammatory tablets, strong loquat loquat, etc. The company has been successively awarded: National Torch Program Key High-tech Enterprise, National Contract-abiding Enterprise, National Postdoctoral Research Workstation, National Enterprise Technology Center, China's Outstanding Private Enterprise, Hunan Provincial Governor's Quality Award Enterprise, Hunan Provincial Exemplary Pharmaceutical Enterprise, Hunan Little Giant Project Enterprise, Hunan Provincial Quality Credit AAA Enterprise, Hunan Cardiovascular Drug Engineering Technology Research Center, Hunan Industrial Brand Cultivation Demonstration Enterprise, 2023 Top 100 Proprietary Chinese Medicine Industry, Innovative Chinese Medicine Brand Enterprise, Hunan Green Factory, Chinese National Pharmaceutical Brand Enterprise Honorary titles such as Top 100 Manufacturing Companies, Law-abiding and Honest Enterprises on the China Pharmaceutical Industry's Most Influential List in the 2021-2023 Pharmaceutical Industry, and High-tech Enterprise.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

116

NMPA:116

Drug Approvals

健胃愈疡颗粒

Approval Number
国药准字Z10960018
Approval Date
Feb 6, 2024
NMPA

Compound Paracetamol and Chlorphenamine Maleate Granules

Product Name
复方氨酚那敏颗粒
Approval Number
国药准字H43021855
Approval Date
Feb 1, 2024
NMPA

Sodium Ibandronate Injection

Product Name
伊班膦酸钠注射液
Approval Number
国药准字H20193013
Approval Date
Nov 3, 2023
NMPA

Cefprozil Tablets

Product Name
头孢丙烯片
Approval Number
国药准字H20093886
Approval Date
Nov 3, 2023
NMPA

益心酮分散片

Approval Number
国药准字Z20090930
Approval Date
Nov 3, 2023
NMPA

Adefovir Dipivoxil Tablets

Product Name
阿德福韦酯片
Approval Number
国药准字H20140073
Approval Date
Sep 25, 2023
NMPA

Tinidazole Suppositories

Product Name
替硝唑栓
Approval Number
国药准字H20093748
Approval Date
Sep 25, 2023
NMPA

独一味咀嚼片

Approval Number
国药准字Z20090260
Approval Date
Jul 5, 2023
NMPA

断血流分散片

Approval Number
国药准字Z20090261
Approval Date
Jul 5, 2023
NMPA

野木瓜胶囊

Approval Number
国药准字Z20090256
Approval Date
Jul 5, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 12
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.